{"id":502807,"date":"2021-06-10T09:33:14","date_gmt":"2021-06-10T13:33:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/"},"modified":"2021-06-10T09:33:14","modified_gmt":"2021-06-10T13:33:14","slug":"pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/","title":{"rendered":"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, June  10, 2021  (GLOBE NEWSWIRE) &#8212; <strong>PAVmed Inc. (Nasdaq: PAVM, PAVMZ<\/strong>) (\u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (\u201cLucid\u201d), has completed European IVDD CE Mark certification of its EsoGuard<sup>\u00ae<\/sup> Esophageal DNA Test (\u201cEsoGuard\u201d).<\/p>\n<p align=\"justify\">Lucid and its EU authorized representative completed the EC declaration of conformity procedure, including the associated technical documentation, ensuring and declaring that EsoGuard meets the essential requirements of Europe\u2019s In-Vitro Diagnostic Medical Devices Directive 98\/79\/EC (\u201cIVDD\u201d). EsoGuard may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom.<\/p>\n<p align=\"justify\">EsoGuard is a molecular diagnostic test, performed on surface esophageal cells collected with Lucid\u2019s EsoCheck<sup>\u00ae<\/sup> Cell Collection Device in a brief non-invasive office procedure. It is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent esophageal cancer deaths through early detection of esophageal precancer and cancer in at-risk chronic heartburn patients. It has been shown to be highly accurate at detecting these conditions in a 408-patient human study published in Science Translational Medicine.<\/p>\n<p align=\"justify\">\u201cWe believe Europe will be an important market for EsoGuard and EsoCheck, where chronic heartburn is as ubiquitous, and esophageal cancer as deadly, as it is in the U.S.,\u201d said Lishan Aklog, M.D., PAVmed\u2019s Chairman and Chief Executive Officer, and Lucid\u2019s Executive Chairman. \u201cWe look forward to leveraging the strong relationships we have already built with European key opinion leaders in esophageal disease who are participating in our pivotal clinical trials, and proceeding with a commercial launch in select European countries in the near future.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About PAVmed<\/strong><br \/>\n        <strong> and Lucid<\/strong>\n      <\/p>\n<p align=\"justify\">PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its major subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer \u2013 the EsoGuard<sup>\u00ae<\/sup> Esophageal DNA Test and EsoCheck<sup>\u00ae<\/sup> Esophageal Cell Collection Device. Its GI Health division also includes the complementary EsoCure\u2122 Esophageal Ablation Device with Caldus\u2122 Technology. Its Minimally Invasive Interventions markets its CarpX<sup>\u00ae<\/sup> Minimally Invasive Device for Carpal Tunnel Syndrome. Another major subsidiary, Veris Health, is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. Other divisions include Infusion Therapy (PortIO\u2122 Implantable Intraosseous Vascular Access Device and NextFlo\u2122 Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yvSOJBZwuQJr-aalgHAsu4AAsLFHPCjRn0GFPMKXhBKljm4ygZyFdyn-wsE7vHgawqWevxFZwhGJ4-6B611RmQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.pavmed.com<\/a>, follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SNbR32ctlWxkfG3qQ6t1E86m_pzH23VvpxCQMY202LPy86zWv51iYHfk1cH7m0ovGEvYgbeBMlYPoFJmCqiXMg==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XigBT3DEVXY9xoNAljIj3G0vByo91tDLEZYLcdYPYjWompxT9gcPZIXJEXsAfAF5SefFi8TD4A8I1JVl0nhPWCawXVWIuNBhhqxvgV6AmPg=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, and watch our videos on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AHGO6sJwdyTOcBr6VBGKr2H7xAv8ows78D1DgEu8UfHR7vZ2lpifPjAxDaOmb1ZZ2JjIiQB1Wqx2zMSEO-v4dRsflC9-0fW1miUMVjXG-Xc36QE3Dg-DK9vR-dY-ykjb\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FAmX-sLU8CxhUHnYsvy_QA7GvZS6aa-bi1bkG6WP4zPCAnTzrpEYnHIbilSdCZiQ8II6Ty6I_HdllOsRMgk-cg==\" rel=\"nofollow noopener\" target=\"_blank\">www.luciddx.com<\/a>, follow Lucid on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SNbR32ctlWxkfG3qQ6t1EyRyZDBPGZrSvX4IBjJxdwhatyx9l7eWXHZkzX4S5kmLeQ2ITF6s6tAnzA5_RxO9hw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, and connect with Lucid on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XigBT3DEVXY9xoNAljIj3L7wnGdIU1J9wpq8fS7EP2Aa6DekvX5GKBsGFAYO4POE2TrRXfTd7Iw8BTy5VNrJlXZoFfUh9XzlLdYwchYdD7o=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>. For detailed information on EsoGuard, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3wjodm0ZGZTY24vZF_lFuaBDEyU_Yuw9AAjKarFYvg6f4MIKl90wW2bsJTLFLSXtVCuvbaYp_WAyDNvPR17Vqw==\" rel=\"nofollow noopener\" target=\"_blank\">www.EsoGuard.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SNbR32ctlWxkfG3qQ6t1Ex3Xav-7HLI6CmZKl-z__lv0AIfVKZCKEhxmy9E9ZN0GVPwip2UNHFenE4fL2ETj8w==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0HXl3qotkznkp55Bjwno9vYBoGikwZLj4JC7TY_jsC40jtA47dMTxS6yY2Zm24qdnbjfVp6Fy_2D5nm-QBvaeQ==\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oacS2dxWevwzjSJfT3lkPM0HmXGQ60clIlmoMUvKlfsGH_iZTUwiOw5XKjm4Lbs2pFgkQzjBnbJ0wMn1DeVMU-bbL6NTkKgY701rzgRzt6Q=\" rel=\"nofollow noopener\" target=\"_blank\">Instagram<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed\u2019s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed\u2019s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed\u2019s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed\u2019s preclinical studies; whether and when PAVmed\u2019s products are cleared by regulatory authorities; market acceptance of PAVmed\u2019s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company\u2019s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed\u2019s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed\u2019s future operations, see Part I, Item IA, \u201cRisk Factors,\u201d in PAVmed\u2019s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, \u201cRisk Factors\u201d in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <u>Investors<\/u><br \/>\n        <br \/>Mike Havrilla<br \/>Director of Investor Relations<br \/>(814) 241-4138<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J1C9bo-aQxLYGtmm9ttQZI0C5ScXhadp57uzCZ8Tkueu2Fna8wyYfiCnUB1L4h-9hfPZ7c-dsFMcqPipcKGWzw==\" rel=\"nofollow noopener\" target=\"_blank\">JMH@PAVmed.com<\/a><\/p>\n<p align=\"justify\">\n        <u>Media<\/u><br \/>\n        <br \/>Shaun O\u2019Neil<br \/>Chief Commercial Officer<br \/>(518) 812-3087<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1Q3GMNf1gzddrUEX_5EQgRr3svBFDYxrWWAeK975_9FpKsTFY8HfIV0_cHLOLSPifK-egCM95Hff4SXgUaaQiA==\" rel=\"nofollow noopener\" target=\"_blank\">SMO@PAVmed.com<\/a><\/p>\n<p>Jim Heins \/ Katie Gallagher<br \/>LaVoieHealthScience<br \/>(646) 491-7042 \/ (617) 792-3937<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l-UAzoQ5XA_OSgv0Hlt18Aem-NgeM3wXqdsFX2I3n1qtHvvvsX5u_gugpW1XtzLUNTPOmeRU1PUVtDWAfzxj1cWUn894R8eiDjLb4VAm8n9zUEyWEw6VwDy7acsuJzJm\" rel=\"nofollow noopener\" target=\"_blank\">PAVmed@lavoiehealthscience.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/2439bcbf-1807-4961-8ba6-6e372061c3fc\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) &#8212; PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (\u201cLucid\u201d), has completed European IVDD CE Mark certification of its EsoGuard\u00ae Esophageal DNA Test (\u201cEsoGuard\u201d). Lucid and its EU authorized representative completed the EC declaration of conformity procedure, including the associated technical documentation, ensuring and declaring that EsoGuard meets the essential requirements of Europe\u2019s In-Vitro Diagnostic Medical Devices Directive 98\/79\/EC (\u201cIVDD\u201d). EsoGuard may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom. EsoGuard is a molecular diagnostic test, performed &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-502807","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) &#8212; PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (\u201cLucid\u201d), has completed European IVDD CE Mark certification of its EsoGuard\u00ae Esophageal DNA Test (\u201cEsoGuard\u201d). Lucid and its EU authorized representative completed the EC declaration of conformity procedure, including the associated technical documentation, ensuring and declaring that EsoGuard meets the essential requirements of Europe\u2019s In-Vitro Diagnostic Medical Devices Directive 98\/79\/EC (\u201cIVDD\u201d). EsoGuard may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom. EsoGuard is a molecular diagnostic test, performed &hellip; Continue reading &quot;PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-10T13:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test\",\"datePublished\":\"2021-06-10T13:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/\"},\"wordCount\":950,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/\",\"name\":\"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==\",\"datePublished\":\"2021-06-10T13:33:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/","og_locale":"en_US","og_type":"article","og_title":"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test - Market Newsdesk","og_description":"NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) &#8212; PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (\u201cLucid\u201d), has completed European IVDD CE Mark certification of its EsoGuard\u00ae Esophageal DNA Test (\u201cEsoGuard\u201d). Lucid and its EU authorized representative completed the EC declaration of conformity procedure, including the associated technical documentation, ensuring and declaring that EsoGuard meets the essential requirements of Europe\u2019s In-Vitro Diagnostic Medical Devices Directive 98\/79\/EC (\u201cIVDD\u201d). EsoGuard may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the United Kingdom. EsoGuard is a molecular diagnostic test, performed &hellip; Continue reading \"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-10T13:33:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test","datePublished":"2021-06-10T13:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/"},"wordCount":950,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/","name":"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==","datePublished":"2021-06-10T13:33:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MjA0MiM0MjM2NDg5IzUwMDA0OTg1OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esoguard-esophageal-dna-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/502807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=502807"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/502807\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=502807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=502807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=502807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}